A polypeptide pharmaceutical composition and its application in treating dry eye symptoms

Abstract

The present invention relates to a polypeptide pharmaceutical composition and its application in treating dry eye symptoms. The present invention provides a polypeptide with strong antioxidant properties, which can be prepared into a pharmaceutical composition for treating dry eye symptoms, especially eye drops, to relieve dry eye symptoms such as dry eye, and has good application prospects.

Description

Technical Field

[0001] The present application relates to the biological field, and specifically to a polypeptide pharmaceutical composition and its application in treating dry eye symptoms. Background Art

[0002] Dry eye is a common chronic ocular surface disease caused by multiple factors that lead to abnormalities in the quality, quantity and dynamics of tears, resulting in decreased tear film stability, accompanied by tissue lesions such as eye discomfort and ocular surface inflammatory reactions.

[0003] At present, there are many commonly used drugs for the treatment of dry eye. In particular, in recent years, many studies have shown that oxidative stress response is closely related to the occurrence and development of dry eye. For example, the levels of DNA oxidative damage product 8-hydroxy-2-deoxyguanosine and late lipid peroxidation markers in the ocular surface tissue and tears of dry eye patients are significantly increased, the antioxidant enzymes in conjunctival cells are reduced, and the level of reactive oxygen species (ROS) is increased. In recent years, more and more studies have begun to explore the potential application of antioxidant therapy in dry eye disease.

[0004] Ginkgo leaf extract has a wide range of pharmacological effects. It can remove reactive oxygen species, improve the body's antioxidant defense function, and prevent lipid peroxidation reactions induced by excessive free radicals from damaging cell membranes. In clinical studies, it was found that Ginkgo leaf extract injection has good efficacy and application value in the treatment of ischemic central retinal vein occlusion. Its mechanism of action is mainly related to anti-oxidation, anti-ischemia, protection of mitochondria, passing through the blood-eye barrier, and inhibition of retinal neovascularization. The occurrence of glaucoma is related to the tolerance of the internal tissues of the eyeball to intraocular pressure. Excessive intraocular pressure can cause optic nerve atrophy and visual field defects, and can also induce the release and accumulation of neurotoxic substances, ultimately inducing glaucoma. Studies on the distribution and number of silver-stained particles in the nuclei of retinal ganglion cells found that Ginkgo leaf extract has a protective effect on retinal ganglion cells under chronic high intraocular pressure in rats. Other studies have found that the combined use of Ginkgo leaf extract and Erigeron breviscapus in clinical glaucoma patients has a synergistic effect on reducing postoperative intraocular pressure, improving visual field, and improving vision in patients.

[0005] In addition, lutein is mainly found in dark green leafy vegetables and is widely distributed in nature. Lutein cannot be synthesized in the human body and is mainly derived from food or dietary supplements. Lutein has an antioxidant effect, which can remove excessive reactive oxygen species in the body, resist damage induced by oxidative stress, and reduce inflammatory responses. The transient retinal ischemia model of rats was induced by high intraocular pressure to observe the survival of retinal neurons. The results showed that lutein can inhibit the synthesis of cyclooxygenase 2 and neuronal nitric oxide synthase in retinal neurons and the oxidative damage caused by ischemia, and inhibit the apoptosis of retinal neurons caused by ischemia. Clinically, the level of retinal macular pigment is closely related to the symptoms of patients with age-related macular degeneration. The level of macular pigment in the retina of patients is significantly low. Sufficient intake of lutein from food or dietary supplements can increase the concentration of macular pigment in the retina. Therefore, supplementing lutein is a simple, safe and effective treatment for age-related macular degeneration.

[0006] SKQ1 is an antioxidant targeting mitochondria. It provides the antioxidant plastoquinone to mitochondria, downregulates ROS levels, blocks oxidative stress on the ocular surface, and thus reduces inflammatory responses. In addition, researchers have also found that SKQ1 can promote corneal epithelial healing and improve tear quality. The results of Phase IIb (VISTA-1) and Phase III clinical trials (VISTA-2) of KQ1 further showed that SKQ1 treatment can significantly reduce corneal staining after 4 weeks of treatment. Selenoprotein P is a secretory protein that is a key molecule involved in the transport and storage of selenium, protecting ocular surface cells from oxidative stress, and maintaining the ocular surface microenvironment. The expression level of selenoprotein P is reduced in patients with dry eye. The latest study confirms that eye drops containing selenium compounds (1% Se-COMP) are expected to become a candidate drug for the treatment of dry eye. Lactoferrin, as an iron-binding protein, is an important antioxidant in tears under physiological conditions. Lactoferrin can scavenge oxygen free radicals and hydroxyls by chelating iron ions, reducing the level of oxidative stress on the ocular surface of patients with dry eye. Clinical studies have found that oral lactoferrin supplementation can significantly improve dry eye symptoms in patients with dry eye secondary to Sjögren's syndrome.

[0007] Although there are some drugs that use antioxidants to treat dry eyes, there are not enough cost-effective drugs at present, and further research and development is needed. Summary of the invention

[0008] The present invention provides a polypeptide pharmaceutical composition with good antioxidant properties. The composition contains the polypeptide of the present invention, and the amino acid sequence of the polypeptide is shown in SEQ ID NO: 1.

[0009] Specifically, the polypeptide is obtained by screening from ginkgo leaves with strong antioxidant activity. The screening is performed by extracting crude protein from ginkgo leaves, enzymolysis with trypsin, intercepting the enzymolysis solution with a molecular weight of 3KDa with an ultrafiltration membrane, separating polypeptides with a DEAE Sepharose FF anion exchange column, further separating the separated components with the best antioxidant properties with a DPPH free radical scavenging ability determination method using sephadex G-25, screening the components with the best antioxidant properties, collecting the main peak with reversed-phase high performance liquid chromatography, and then identifying the amino acid sequence to obtain a sequence as shown in SEQ ID NO: 1, named GL-OF antioxidant peptide.

[0010] Specifically, the pharmaceutical composition of the present invention further contains other suitable components, such as excipients.

[0011] Unless otherwise clearly stated, the excipient used herein may refer to compounds used as or commonly referred to as fillers, diluents, loosening agents, etc., it should be understood that these names are not exhaustive, and they are not exclusive, such as specific excipients can be used as both diluents and fillers. Unless otherwise clearly stated, the excipient used herein may refer to compounds used as or commonly referred to as binders, coatings, disintegrants, sweeteners, flavoring agents and glidants. Excipients can affect the stability, organoleptic properties and / or physical properties of the given preparation. In the given active preparation, the weight ratio of the active to the excipient can be changed to change the treatment, physics, appearance and / or organoleptic properties of the given preparation. Suitable types of excipients for solid dosage forms include: binders, disintegrants, dispersants, fillers, sweeteners, glidants, flavoring agents, surfactants, wetting agents, preservatives and diluents. Although conventional pharmaceutical excipients can be used, they may not always work in exactly the same way as traditional drug processing. Adding at least one excipient to the preparation of the active substance can affect the properties of the preparation such as hardness, dispersion time, brittleness, dosage form size and the drug dosage in the dosage form. If the excipient content in the particles containing the drug is too low, the performance of administration can be sacrificed. If the excipient content in the particles containing the drug is too high, the dosage form size may have to be increased so that the active substance of the appropriate dose is included. Binders Binders are subclasses of excipients that can be added to solid preparations. The solid preparation of the active substance is usually a binder, which is a compound that promotes the association between particles in the solid preparation, such as the same or other active substances and / or other components, including other excipients, such as sweeteners, flavorings and preservatives. Suitable binders that can be used for the preparation of the present invention include, but are not limited to, gelatin, cellulose, cellulose derivatives, polyvinyl pyrrolidone, starch and sugar. Exemplary binders include, but are not limited to, spray-dried lactose, fructose, sucrose, glucose, sorbitol, mannitol, xylitol.

[0012] Further, the pharmaceutical composition of the present invention also contains a suitable surfactant or co-surfactant. The concentration of the surfactant system in the solid oral dosage form should be sufficient to provide a preparation that can be easily manufactured, stored and applied to human or animal patients. In solid preparations, the inclusion of surfactants in printing fluids, bulk powders and particles containing active substances helps to ensure that the dosage form disperses rapidly when placed in a minimum amount of water. Surfactants can be used to enhance the wetting of particles. Surfactants only need to be present in an amount sufficient to enhance dispersion (compared to another dosage form prepared without surfactants). However, if the surfactant is present in too high an amount, it can adversely affect the mouthfeel, performance and / or physical properties of the dosage form. Surfactants can be contained in particles, bulk powders and / or printing fluids containing active substances. In some embodiments, based on the weight of the particles containing the drug, the total amount of surfactants present in the particles containing the drug is about 0.5% by weight, >0.5% by weight, 1-4.5% by weight, 2-3% by weight. In some embodiments, the amount of surfactant present in the bulk powder is about 0.5 wt%, >0.5 wt%, 1-5 wt%, 2-3 wt%, based on the weight of the bulk powder, excluding particles containing the active.

[0013] Furthermore, the pharmaceutical composition of the present invention is an eye drop.

[0014] The aqueous liquid preparation of the present invention may further contain an isotonicity agent (e.g., potassium chloride, boric acid, glycerol, propylene glycol, mannitol, sorbitol, glucose, etc.), a buffer (e.g., phosphate buffer, acetate buffer, borate buffer, citrate buffer, glutamic acid, ε-aminocaproic acid, etc.), a preservative (benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, chlorobutanol, benzyl alcohol, sodium dehydroacetate, parabens, etc.), a thickener (methylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, sodium hyaluronate, carboxyvinyl polymer, polyvinyl alcohol, polyvinyl pyrrolidone, polyethylene glycol, etc.), a pH adjuster (hydrochloric acid, sodium hydroxide, acetic acid, phosphoric acid, etc.), a stabilizer (sodium edetate, citric acid, etc.), and others as appropriate.

[0015] The viscosity of the eye drops of the present invention is usually about 15 to 150 mPa·s at 20°C, and the amount of sodium chloride introduced into the preparation for suppressing precipitation formation and viscosity reduction is at least 0.2 w / v% or more, preferably 0.2 to 1.8 w / v%, more preferably 0.2 to 1.5 w / v%, and further preferably 0.7 to 1.0 w / v%, based on the total amount of the aqueous liquid preparation. For example, the amount of sodium chloride introduced for suppressing precipitation formation is at least 0.2 w / v% or more, preferably 0.2 to 1.8 w / v%, more preferably 0.2 to 1.0 w / v%, based on the total amount of the aqueous liquid preparation. For example, the amount of sodium chloride introduced for suppressing viscosity reduction is at least 0.2 w / v% or more, preferably 0.2 to 1.8 w / v%, more preferably 0.5 to 1.5 w / v%, and further preferably 0.7 to 1.0 w / v%, based on the total amount of the aqueous liquid preparation.

[0016] The pH of the eye drops of the present invention is usually 5 to 8, preferably 5.5 to 7.5, further preferably 5.8 to 7.2, and particularly preferably 6 to 7.

[0017] The aqueous liquid preparation of the present invention may further contain an isotonicity agent (e.g., potassium chloride, boric acid, glycerol, propylene glycol, mannitol, sorbitol, glucose, etc.), a buffer (e.g., phosphate buffer, acetate buffer, borate buffer, citrate buffer, glutamic acid, ε-aminocaproic acid, etc.), a preservative (benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, chlorobutanol, benzyl alcohol, sodium dehydroacetate, paraoxybenzoic acid esters, etc.), a thickener (methylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, sodium hyaluronate, carboxyvinyl polymer, polyvinyl alcohol, polyvinyl pyrrolidone, polyethylene glycol, etc.), a pH adjuster (hydrochloric acid, sodium hydroxide, acetic acid, phosphoric acid, etc.), a stabilizer (sodium ethylenediaminetetraacetate, citric acid, etc.), and others as appropriate.

[0018] The eye drops of the present invention further contain a preservative, examples of which include quaternary ammonium salts such as benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, etc., parahydroxybenzoic acid esters such as methylparaben, ethylparaben, propylparaben, butylparaben, etc., benzyl alcohol, sorbic acid, sodium thiomercalate, chlorobutanol, sodium dehydroacetate, etc.

[0019] The eye drops of the present invention further contain a chelating agent. Examples of the chelating agent include sodium edetate, citric acid, etc., and examples of the cooling agent include 1-menthol, borneol, camphor, eucalyptus oil, etc.

[0020] In some cases, higher doses are required. In such cases, the polypeptide is administered at about 120 μg to 150 μg per eye. In some cases, the dose of the polypeptide is at least 80 μg, at least 90 μg, at least 100 μg, at least 110 μg, at least 120 μg, at least 130 μg, or at least 140 μg per eye. In some cases, the dose of the polypeptide is less than 170 μg, less than 160 μg, less than 150 μg, less than 140 μg, less than 130 μg, or less than 120 μg per eye. In some cases, even higher doses are required. For example, the dose of the polypeptide can be at least 170 μg, at least 180 μg, at least 190 μg, at least 200 μg, at least 210 μg, at least 220 μg, at least 230 μg, at least 240 μg, at least 250 μg, at least 260 μg, at least 270 μg, at least 280 μg, at least 290 μg, at least 300 μg, at least 320 μg, at least 340 μg, at least 360 μg, at least 380 μg, at least 400 μg. In some embodiments, the present invention relates to an agent that is at least 1 mg, at least 1.1 mg, at least 1.2 mg, at least 1.3 mg, at least 1.4 mg, at least 1.5 mg, at least 1.6 mg or at least 1.7 mg. In some embodiments, the present invention relates to an agent that is at least 1.1 mg, at least 1.2 mg, at least 1.3 mg, at least 1.4 mg, at least 1.5 mg, at least 1.6 mg or at least 1.7 mg.

[0021] Administration can be once a day, twice a day, three times a day, four times a day, five times a day, six times a day, seven times a day, eight times a day, nine times a day, ten times a day, or more than ten times a day. Administration is preferably twice a day. In some preferred cases, administration is more than twice a day, such as three or four times a day. In some preferred cases, administration is less than four times a day, or less than three times a day, or twice a day or once a day. In particularly preferred cases, administration is twice a day. In some cases, treatment comprises administering the polypeptide once a day. In some cases, treatment comprises administering the polypeptide at a frequency less than once a day, such as once every two days, once every three days, once a week, or once every two weeks.

[0022] Beneficial Effects

[0023] The present invention provides a polypeptide with strong antioxidant properties. The polypeptide can be prepared into a pharmaceutical composition for treating dry eye symptoms, especially eye drops, to relieve dry eye symptoms such as dry eye, and has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 Effect of peptides on apoptosis of HCEC human corneal endothelial cells

[0025] Figure 2 Effects of peptides on the number of goblet cells in a mouse dry eye model DETAILED DESCRIPTION

[0026] The specific embodiments of the present invention will be described in more detail below with reference to the accompanying drawings. Although the specific embodiments of the present invention are shown in the accompanying drawings, it should be understood that the present invention can be implemented in various forms and should not be limited by the embodiments set forth herein. On the contrary, these embodiments are provided in order to enable a more thorough understanding of the present invention and to enable the scope of the present invention to be fully communicated to those skilled in the art.

[0027] Example 1 Identification of the antioxidant properties of GL-OF antioxidant peptide

[0028] The concentration of the synthesized GL-OF antioxidant peptide was adjusted to 0.5 mg / mL for later use.

[0029] Take 0.2mL of the peptide sample and add it to 0.2mL of 0.2mmol / L DPPH methanol solution, and shake it evenly. Place it in the dark for 20 minutes, and measure the absorbance of the supernatant at 517nm (As). Use water instead of the sample solution as a control (Ac). Add 0.2mL of methanol to 0.2mL of water as a blank zero. The DPPH scavenging ability of the peptide sample is expressed by the scavenging rate (%), and the formula is [(Ac-As) / Ac]×100.

[0030] Superoxide anion radical (O2 -. ) Determination of scavenging ability: Adopt the pyrogallol self-oxygenation method. Take 1.5mL of 50mmol / L Tris-HCl buffer (pH8.3) containing 1mM EDTA and 0.5mL of sample solution and add them to the colorimetric tube and mix well. Add 1mL of 3mM pyrogallol dissolved in 10mM hydrochloric acid, mix quickly, measure the absorbance every 30s at 420nm, and end after 3min. Make a regression equation with time against absorbance, and its slope is the rate of superoxide free radical generation, recorded as (△A / mins). Use water instead of sample solution as control (△A / minc). Add 1.5ml of Tis-HCl buffer to 1.5ml of water for blank zero adjustment. The ability of the enzymatic solution sample to scavenge superoxide anion free radicals is expressed by the scavenging rate (%), and the formula is [(△A / min s-△A / minc) / △A / min s]×100.

[0031] The hydroxyl radical (·OH) scavenging ability was determined by the o-phenanthroline method. Take 0.5 ml of sample and add 1 mL of 0.15 M phosphate buffer (pH 7.4), then add 0.5 ml of 1.8 mM o-phenanthroline solution dissolved in buffer and 0.5 ml of 1.8 mM FeS04 aqueous solution, mix quickly, and finally add 0.5 ml of 0.02% (W / V) H202, water bath at 37°C for 60 min, and measure its absorbance at 536 nm (As). Use water instead of sample as control (Ac). Use water instead of sample and H202 as blank (Ab). Add 1.5 ml of water to 1.5 ml of phosphate buffer to adjust to zero. The ability of the enzymatic solution sample to scavenge hydroxyl radicals is expressed by the scavenging rate (%), the formula is [As-Ac) / Ab-Ac)]×100. Use the same concentration of GSH as a reference. The results are shown in Table 1.

[0032] Table 1 Identification results of antioxidant properties of GL-OF antioxidant peptides

[0033]

[0034] As can be seen from Table 1, the GL-OF antioxidant peptide of the present invention has good DPPH scavenging ability, superoxide anion radical (O2-.) scavenging ability and hydroxyl radical (·OH) scavenging ability, which are close to the activity of GSH at the same concentration, especially the former and the latter have better effects.

[0035] Example 2 Cytological Experiment on Antioxidant Properties of GL-OF Antioxidant Peptide

[0036] Reactive oxygen free radicals are an important factor causing corneal endothelial cell damage. Therefore, finding effective antioxidant drugs to inhibit corneal endothelial cell damage caused by free radicals has important application value in the treatment of dry eye disease.

[0037] HCEC human corneal endothelial cells (Cat. No. LM-009, LMAIBio) were routinely cultured in DMEM / F12 culture medium containing 100mL / L fetal bovine serum at 50ml / LCO2 and 37℃. After the cells covered the bottom of the culture bottle, they were digested and collected with 2.5g / L trypsin, inoculated into a new culture bottle at a ratio of 1 / 2, and 5mL of complete culture medium was added for subculture. After the cells were inoculated and cultured for 24h as described above, they were pretreated with peptides at concentrations of 10, 50, 100 and 200μg / mL for 30min, and then 600μmol / L H202 was added for further culture. Three parallel wells were taken for each group, and HCEC without peptide and H202 and other conditions were the same was used as a negative control, and HCEC without peptide pretreatment and directly added with 600μmol / L H202 and other conditions were the same was used as a positive control. Observe and take pictures under an inverted microscope every 2h.

[0038] HCECs were collected after 8 h of treatment with different methods, and the cell density was adjusted to 2×10 9 / L~2×10 10 / L. Take 0.1mL of cell suspension. Add 4μl of acridine orange / ethidium bromide (AO / EB) solution (100mg / L AO solution: 100mg / L EB solution = 1:1), stain at room temperature for 1min, then drop on a non-fluorescent slide, cover with a slide and observe under a fluorescence microscope and take pictures. Count at least 300 cells for each sample. Calculate the cell apoptosis rate based on the fact that the cell nucleus with orange-red fluorescence is apoptotic cells and the cell nucleus with bright green fluorescence is normal cells: number of apoptotic cells / (number of normal cells + number of apoptotic cells) × 100%. The results are as follows: Figure 1 shown.

[0039] from Figure 1 The results of AO / EB double staining of HCEC pretreated with peptides and then treated with H202 showed that 10μg / mL, 50μg / mL, 100μg / mL and 200μmol / L peptide pretreatment can significantly reduce HCEC apoptosis caused by 600μmol / L H202, and the apoptosis rate gradually decreased with the increase of concentration in the concentration range of 10-100μg / mL. However, when the concentration increased to 200μg / mL, the apoptosis rate was not as low as that of 100μg / mL, indicating that high concentrations of peptides still have a certain inhibitory effect. Therefore, the effect of selecting 100μg / mL of peptide is the best.

[0040] Example 3 Verification of the therapeutic efficacy of polypeptide eye drops on dry eye mouse model

[0041] The mouse dry eye model was prepared by a conventional dry eye model preparation method in the art (eg, He Huan et al., Chinese Journal of Ophthalmology, Issue 1, 2012).

[0042] Healthy male BALB / c mice, weighing (21±3) g, were kept in a standard environment with a temperature of 25°C and a relative humidity of less than 55%. Mice with dry eye symptoms were induced by eye drops of benzalkonium chloride solution (0.25%, 5 μl each time, 2 times / d). The clinical indicators of the model mice were statistically analyzed and calculated as the mean of each clinical indicator. The mice with the closest clinical indicators within the range of mean ± standard deviation were selected for subsequent treatment experiments.

[0043] With blank mice as control, model mice were randomly divided into 5 groups, namely model control, 0.1% sodium hyaluronate (Qilu Pharmaceutical, Runyi) positive control group, saline containing 10μg / mL polypeptide (low-dose treatment group), saline containing 50μg / mL polypeptide (medium-dose treatment group), and saline containing 100μg / mL polypeptide (high-dose treatment group), 3 times / d, 5μl each time. BUT, sodium fluorescein staining and corneal inflammation index were scored on the 6th day after treatment. Specifically: BUT: 1ml of 1% liquid sodium fluorescein was dropped into the conjunctival sac and closed, and then observed under cobalt blue light of slit lamp microscope. After 3 blinks, the time from the last blink to the appearance of the first black spot on the cornea was BUT. Corneal sodium fluorescein staining score: 90s after the instillation of sodium fluorescein, corneal epithelial sodium fluorescein staining was graded under cobalt blue light of slit lamp microscope. The cornea was divided into 4 quadrants and scored separately, and all scores were added up to get the final score. Scoring criteria: no staining: 0 points; less than 30 punctate staining: 1 point; more than 30 punctate staining but not diffuse: 2 points; severe diffuse staining but no plaque staining: 3 points; plaque staining: 4 points. Corneal inflammation index: The corneal inflammation index was evaluated using a slit light band. The inflammation index consists of 3 parts: ciliary congestion (no congestion: 0 points; congestion band but width less than 1mm: 1 point; congestion band width greater than 2mm: 3 points); central corneal edema (no edema: 0 points; mild edema, iris texture is still clear: 1 point; moderate edema, iris texture is unclear: 2 points; iris and pupil are not visible: 3 points); peripheral corneal edema (scoring criteria are the same as central corneal edema). The final corneal inflammation index is the sum of the scores of the three parts divided by 9. The results are shown in Table 2.

[0044] Table 2 Data of relevant indicators of mice in each group after treatment

[0045]

[0046] As can be seen from Table 2, after the peptide treatment of each group of mice, the tear film stability can be effectively improved, the corneal inflammation index can be reduced, and thus the dry eye treatment effect of mice can be improved.

[0047] Furthermore, the eye tissue was removed and the corresponding histological staining was performed. Those with dark red cytoplasm staining were conjunctival goblet cells. Six sections at different equal positions were taken from each eye and counted separately. The average value was taken as the number of goblet cells in that eye. The results are as follows: Figure 2 shown.

[0048] from Figure 2 It can be seen that the polypeptide of the present invention can inhibit cell apoptosis, reduce damage to goblet cells, increase the number of goblet cells and thus be used for the treatment of dry eyes through anti-oxidation.

[0049] When implementing or testing the embodiments of the present invention, optional methods and materials similar or equivalent to the methods and materials described in this specification may be used, and preferred methods, devices, and materials are described in this specification. However, before describing the materials and methods of the present invention, it should be understood that the specific size, shape, dimensions, materials, methods, means, etc. described in this specification may be changed according to conventional experimental methods and optimization purposes, and therefore the present invention is not limited thereto. It should also be understood that the technical terms used in this specification are only used to illustrate specific types or embodiments and are not used to limit the scope of the present invention, which is limited only by the scope of the appended claims.

Claims

1. A GL-OF antioxidant peptide having antioxidant properties, characterized in that The amino acid sequence of the GL-OF antioxidant peptide is shown in SEQ ID NO:

1.

2. Use of the GL-OF antioxidant peptide according to claim 1 in the preparation of a pharmaceutical composition for treating dry eye symptoms.

3. The use according to claim 2, characterized in that The pharmaceutical composition is eye drops.

Images